Ablynx initiates Phase I/II trial for ALX-0061 (Anti-IL-6R) in patients with rheumatoid arthritis
30-Mar-2011 -
Ablynx announced that it had initiated a double-blind, randomised, placebo-controlled Phase I/II study with ALX-0061, a Nanobody targeting the interleukin 6 receptor (IL-6R), in patients with rheumatoid arthritis (RA).IL-6 and its receptor IL-6R are involved in the pathogenesis of various ...
inflammatory diseases
rheumatoid arthritis